Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
Journal of Neurology Neurosurgery & PsychiatryPublished 25 July 2008
Paul Edison, Christopher C. Rowe, Juha O. Rinne, Siew Hiang Sally Ng, Imtiaz Ahmed, Nina Kemppainen
Citations427
SJR quartileQ1
SJR score3.38
SNIP2.41
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is suggested that the presence of amyloid in DLB could contribute to the rapid progression of dementia in this condition and that anti-amyloid strategies may be relevant.
Abstract
This study suggests that amyloid load is significantly raised in over 80% of subjects with DLB, while amyloid pathology is infrequent in PDD. These in vivo PET findings suggest that the presence of amyloid in DLB could contribute to the rapid progression of dementia in this condition and that anti-amyloid strategies may be relevant.
Keywords
Medicine
Journal of Psychiatric Research“Mini-mental state”
86,858 Citations1975Marshal F. Folstein, Susan E. Folstein +1 more
A simplified, scored form of the cognitive mental status examination, the “Mini-Mental State” (MMS) which includes eleven questions, requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
NeurologyDiagnosis and management of dementia with Lewy bodies
4,968 Citations2005Ian G. McKeith, Dennis W. Dickson +43 more
Annals of NeurologyImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
4,477 Citations2004William E. Klunk, Henry Engler +19 more
The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.
NeurologyThe Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease
4,050 Citations1989J. C. Moms, Albert Heyman +6 more
Although information on validation is limited thus far, the CERAD batteries appear to fill a need for a standardized, easily administered, and reliable instrument for evaluating persons with AD in multicenter research studies as well as in clinical practice.
Movement DisordersClinical diagnostic criteria for dementia associated with Parkinson's disease
3,035 Citations2007Murat Emre, Dag Aarsland +21 more
Clinical diagnostic criteria for probable and possible PD‐D are proposed, characterized by impairment in attention, memory, executive and visuo‐spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent.
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
2,416 Citations2002Gerda G. Fillenbaum, Albert Heyman
Nature MedicinePeripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
2,006 Citations2000Frédérique Bard, Catherine Cannon +21 more
Results indicate that antibodies can cross the blood–brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.
Human Brain MappingThree‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe
1,336 Citations2003Alexander Hammers, R. Allom +7 more
This work has expanded and refined existing algorithms for the subdivision of MRI datasets into anatomical structures, and used the normalized superimposed atlases to create a maximum probability map in stereotaxic space, which retains quantitative information regarding inter‐subject variability.
Proceedings of the National Academy of SciencesPeripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
1,298 Citations2001Ronald B. DeMattos, Kelly R. Bales +4 more
It is found that a monoclonal antibody (m266) directed against the central domain of A beta was able to bind and completely sequester plasma A beta in transgenic mouse models of Alzheimer's disease.
Annals of NeurologyInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ <sub>42</sub> in humans
1,253 Citations2005Anne M. Fagan, Mark A. Mintun +11 more
Amyloid‐β42 (Aβ42) appears central to Alzheimer's disease pathogenesis and is a major component of amyloid plaques, and its decrease may reflect plaques acting as an Aβ42 “sink,” hindering transport of soluble A β42 between brain and CSF.
NeurologyImaging β-amyloid burden in aging and dementia
1,099 Citations2007C. C. Rowe, Sally Ng +18 more
Pittsburgh Compound B PET findings match histopathologic reports of β-amyloid (Aβ) distribution in aging and dementia, and suggest that Aβ may influence the development of dementia with Lewy bodies, and therefore strategies to reduce A β may benefit this condition.
Neurology[ <sup>11</sup> C]PIB in a nondemented population
1,030 Citations2006Mark A. Mintun, Gina LaRossa +8 more
Elevated [11C]PIB binding in nondemented subjects suggests that [11 C]P IB amyloid imaging may be sensitive for detection of a preclinical Alzheimer disease state.
Archives of NeurologyA Clinicopathologic Study of 100 Cases of Parkinson's Disease
950 Citations1993Andrew Hughes, S. E. Daniel +2 more
The clinical details of 100 cases of histologically confirmed Parkinson's disease were examined and correlated with pathologic findings, finding the general pattern of disease conformed to traditional descriptions, and the findings broaden the present clinical and pathologic spectrum of Parkinson's Disease.
Journal of Cerebral Blood Flow & MetabolismKinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B
719 Citations2005Julie C. Price, William E. Klunk +8 more
It was shown that it is feasible to perform quantitative PIB PET imaging studies that are needed to validate simpler methods for routine use across the AD disease spectrum and the Logan analysis was the method-of-choice for the PIBPET data as it proved stable, valid, and promising for future larger studies and voxel-based statistical analyses.
BrainTwo-year follow-up of amyloid deposition in patients with Alzheimer's disease
609 Citations2006Henry Engler, Anton Forsberg +8 more
Relatively stable PIB retention after 2 years of follow-up in patients with mild Alzheimer's disease suggests that amyloid deposition in the brain reaches a plateau by the early clinical stages of Alzheimer’s disease and therefore may precede a decline in rCMRGlc and cognition.
NeurologyAlpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
608 Citations2000Howard I. Hurtig, John Q. Trojanowski +9 more
CLBs detected by α-synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia than the presence of Alzheimer’s pathology, which was present in a minority of the cases in this series.
PubMedSimplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
541 Citations2005Brian J. Lopresti, William E. Klunk +9 more
Of the simplified methods for PIB analysis examined, CAR90 provided DVR measures that were most comparable to ART90; CER90 was the most reproducible and SUVR90 produced the largest effect size.
NeurologyAmyloid, hypometabolism, and cognition in Alzheimer disease
503 Citations2006Paul Edison, Hilary Archer +10 more
The high frontal amyloids load detected by [11C]PIB-PET in AD in the face of spared glucose metabolism is of interest and suggests that amyloid plaque formation may not be directly responsible for neuronal dysfunction in this disorder.
Annals of NeurologyImaging of amyloid burden and distribution in cerebral amyloid angiopathy
495 Citations2007Keith A. Johnson, Matt Gregas +13 more
It is hypothesized that amyloid deposition would be observed with PiB in CAA, and based on the occipitals predilection of CAA pathology and associated hemorrhages, that specific PiB retention would be disproportionately greater in occipital lobes.
PubMedPerformance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association.
479 Citations1997Gunnar Brix, J. Zaers +8 more
The ECAT EXACT HR+ has an excellent, nearly isotropic spatial resolution, which is advantageous for brain and small animal studies, and offers a sufficient sensitivity and count rate capacity for fully three-dimensional whole-body imaging.
Archives of NeurologyParkinson Disease Neuropathology
399 Citations2002Hülya Apaydın, J. Eric Ahlskog +3 more
Diffuse or transitional Lewy body disease is the primary pathologic substrate for dementia developing later in Parkinson disease and seemed to account for end-stage, levodopa refractory parkinsonism, suggesting common origins or one triggering the other.
Journal of NeuroscienceAmyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees
389 Citations2007William E. Klunk, Julie C. Price +19 more
Postmortem evaluation of tissue from two parents of PS1C410Y subjects in this study confirmed extensive striatal amyloid deposition, along with typical cortical deposition, in these PS1 mutation carriers.
NeurologyA 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease
372 Citations2000Thomas A. Hughes, Hernert Ross +5 more
Dementia in PD is likely to reflect interaction of the neuropathology of the basal ganglia and age-related pathology, and the findings do not support the division of PD into early and late-onset cases.
Acta NeuropathologicaAlpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease
371 Citations2000P. M. Mattila, Juha O. Rinne +4 more
It is shown, for the first time, that in PD, alpha-synuclein-positive cortical LBs are associated with cognitive impairment independent of AD-type pathology.
PubMedMolecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
340 Citations2007Brian J. Bacskai, Matthew P. Frosch +11 more
It is confirmed that PiB detects Abeta in the living patient and demonstrates that amyloid deposited as cerebral amyloids angiopathy can be the dominant source of signal.
NeurologyDifferences in neuropathologic characteristics across the Lewy body dementia spectrum
340 Citations2006Clive Ballard, I. Ziabreva +6 more
There is a gradation of these differences across the dementia with Lewy bodies/Parkinson disease dementia spectrum and the findings do not support an arbitrary cut-off between the two disorders.
American Journal of Geriatric PsychiatryIn-Vivo Imaging of Alzheimer Disease -Amyloid With [11C]SB-13 PET
316 Citations2004N. P. L. G. Verhoeff
Preliminary PET data indicate that [11C]SB-13 is an effective PET tracer for fibrillar Abeta imaging in vivo, with similar performance as [ 11C]PIB, and the two radiotracers demonstrated similar binding properties.
Journal of NeuroscienceThe Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component
308 Citations2003William E. Klunk, Yanming Wang +8 more
The data suggest that the binding of BTA-1 to AD brain is dominated by a specific interaction with Aβ amyloid deposits.
BrainPIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
304 Citations2007Andrew Lockhart, Janette Lamb +7 more
The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Abeta-peptide related cerebral amyloidosis.
Acta NeuropathologicaCortical Lewy body pathology in the diagnosis of dementia
297 Citations2001Antony J. Harding, Glenda M. Halliday
It is suggested that dual pathologies cause DLB, and high densities of parahippocampal Lewy bodies indicate dementia regardless of additional pathologies.
Journal of Nuclear MedicineVisual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease
256 Citations2007Siew Hiang Sally Ng, VL Villemagne +12 more
Visual analysis of 11C-PIB images appears more accurate than visual reading of 18F-FDG for identification of AD and has accuracy similar to quantitative analysis of a 90-min dynamic scan, which is limited by cortical binding in some healthy elderly subjects.
NeurologyVoxel-based analysis of PET amyloid ligand [ <sup>11</sup> C]PIB uptake in Alzheimer disease
223 Citations2006Nina Kemppainen, Sargo Aalto +10 more
Voxel-based analysis revealed widespread distribution of increased [11C]PIB uptake in Alzheimer disease (AD), in accordance with the distribution and phases of amyloid pathology in AD, previously documented in postmortem studies.
Journal of Geriatric Psychiatry and NeurologyIntellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates
206 Citations1988Jeffrey L. Cummings
Investigation of Parkinson's disease patients reveals that PD patients manifest impairment in memory, visuospatial skills, and set aptitude, and the more severe dementia syndromes have cholinergic alterations or Alzheimer's disease.
NeurologyClinical and quantitative pathologic correlates of dementia with Lewy bodies
202 Citations1999Estrella Gómez‐Tortosa, Kathy L. Newell +4 more
There is a consistent pattern of vulnerability to LB formation across subcortical, paralimbic, and neocortical structures that is similar for DLB cases with or without concomitant AD, suggesting that DLB should not be considered just a severe form of PD.
Annals of NeurologyAmyloid load and cerebral atrophy in Alzheimer's disease: An <sup>11</sup>C‐PIB positron emission tomography study
180 Citations2006Hilary Archer, Paul Edison +6 more
A positive correlation between rates of whole brain atrophy and whole brain (p = 0.019) and regional 11C‐PIB uptake provides support for the central role of amyloid deposition in the pathogenesis of AD.
Journal of Neuroscience<i>In Vitro</i>Characterization of Pittsburgh Compound-B Binding to Lewy Bodies
159 Citations2007Michelle T. Fodero‐Tavoletti, David P. Smith +14 more
It is indicated that PIB retention observed within the cortical gray matter regions of DLB subjects in [11C]-PIB PET studies is largely attributable to PIB binding to Aβ plaques and not Lewy bodies.
Acta NeuropathologicaDoes striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
151 Citations2006K. A. Jellinger, Johannes Attems
Differences in AS and Aß pathologies and much less of tau lesions in the striatum support a morphologic distinction between PDD and DLB, which may be of pathophysiologic importance, but the causes of these differences are unclear.
NeuroImage[11C]PIB binding in Parkinson's disease dementia
133 Citations2007Walter Maetzler, Matthias Reimold +13 more
It is suggested that PIB-PET can be used to further differentiate PDD with respect to cortical amyloid and evidence that--in addition to nonspecific binding--PIB uptake in the brainstem may also reflect PDD related amyloids.
NeuroImageEvaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease
119 Citations2006Scott K. Ziolko, Lisa A. Weissfeld +6 more
The results of the present study indicate that voxel-based methods will be useful for future larger longitudinal studies of amyloid deposition that could improve AD diagnosis and anti-amyloid therapy assessment.
PubMedImaging characteristics of a 3-dimensional GSO whole-body PET camera.
113 Citations2004Suleman Surti, Joel S. Karp
This whole-body scanner represents a new generation of 3D, high-sensitivity, and high-performance PET cameras capable of producing high-quality images in <30 min for a full patient scan and shows no noticeable degradation in image contrast at high activity levels.
Movement DisordersPrevalence of amyloid‐β deposition in the cerebral cortex in Parkinson's disease
71 Citations2002Frank Mastaglia, R. Johnsen +2 more
It is confirmed that dementia in PD is only infrequently due to fully established Alzheimer's disease, however, vascular and parenchymal Aβ deposition could still contribute to dementia and cognitive decline when combined with other changes such as α‐synuclein deposition in the cerebral cortex and cortical Lewy bodies.
Movement DisordersAmyloid β‐peptide and the dementia of Parkinson's diease
46 Citations1996K. Jendroska, Andrew J. Lees +2 more
The authors' data found no increase of either AD or “early” Alzheimer‐type pathology in cases of PD; however, a synergistic effect between the two pathologies was suggested as contributing to dementia.
Dementia and Geriatric Cognitive DisordersBeta-Amyloid Deposition in the Temporal Lobe of Patients with Dementia with Lewy Bodies: Comparison with Non-Demented Cases and Alzheimer’s Disease
38 Citations2000Richard A. Armstrong, N.J. Cairns +1 more
The results suggest that pure DLB and AD are distinct disorders which can coexist in some patients, however, the Aβ pathology of DLB/AD cases is not identical to that observed in patients with AD alone.
Movement DisordersDystonia gravidarum: A new entity?
37 Citations2005Erle Chuen‐Hian Lim, Raymond C.S. Seet +2 more
C cervical dystonia occurring in a 31‐year‐old, previously well, primigravid, primiparous Chinese woman at 4 weeks' amenorrhea is described, which was ameliorated with low‐dose clonazepam and disappeared completely by the end of the second trimester without recurring despite her being tapered off benzodiazepine therapy.
Neuropathology and Applied NeurobiologyAmyloid β protein (Aβ) deposition in dementia with Lewy bodies: predominance of Aβ<sub><b>42(43)</b></sub> and paucity of Aβ<sub><b>40</b></sub> compared with sporadic Alzheimer’s disease
30 Citations1998Mann, Marie-Juliet Brown +3 more
The density of Lewy bodies in DLB was unrelated to the extent of Aβ deposition, although those cases possessing one or more copies of the apolipoprotein E E4 allele had a higher LB density than those without an E 4 allele, suggesting that the apoE E4 isoform might facilitate, though not necessarily trigger, the formation of LB in susceptible individuals.
PubMedProgress towards testing the amyloid hypothesis: inhibitors of APP processing.
20 Citations2001Richard E. Olson, R A Copeland +1 more
Recent progress in understanding the beta- and gamma-secretase activities required for the formation of A beta peptide is summarized and therapeutic strategies aimed at inhibiting these activities are discussed.
CNS SpectrumsUtilizing Advanced Imaging and Surrogate Markers Across the Spectrum of Alzheimer's Disease
13 Citations2005Mark A. Mintun
Pittsburgh Compound-B (PIB), a benzothiazole analog, has recently been found to specifically label amyloid deposits in positron emission tomography (PET) studies of the brain, opening the door for a wide range of applications related to Alzheimer's disease.